Welcome to our dedicated page for Champions Oncolo news (Ticker: CSBR), a resource for investors and traders seeking the latest updates and insights on Champions Oncolo stock.
Champions Oncology, Inc. (CSBR) delivers cutting-edge solutions in personalized cancer research through its clinically validated tumorgraft and PDX platforms. This news hub provides investors and researchers with essential updates on the company’s scientific advancements, strategic partnerships, and operational milestones.
Access timely press releases covering key developments including clinical study results, technology licensing agreements, and regulatory progress updates. Our curated collection helps stakeholders track CSBR’s contributions to improving oncology drug development efficiency and patient-specific treatment strategies.
Discover updates across three core areas: platform innovations enhancing predictive cancer modeling, biopharma collaborations accelerating therapeutic discovery, and financial disclosures detailing sustainable growth. Each announcement is vetted for relevance to CSBR’s mission of transforming translational oncology research.
Bookmark this page for direct access to primary source materials from Champions Oncology. Regularly updated content ensures you stay informed about breakthroughs in patient-derived xenograft applications and their impact on precision medicine development.
Champions Oncology (NASDAQ:CSBR) reported record annual revenue of $41 million for the fiscal year ending April 30, 2021, marking a 28% year-over-year growth. The fourth quarter alone saw revenue rise by 21% to $10.6 million. Significant investments in research, development, and new service capabilities contributed to an operating income of $2.1 million, reversing prior losses. The company's gross margin improved to 48%. Despite a net cash use of $1.7 million for the year, the company ended with $4.7 million in cash and no debt.
Champions Oncology (NASDAQ:CSBR) will release its fourth quarter financial results on July 22, 2021, before market open. The company specializes in oncology technology solutions aimed at enhancing drug discovery through advanced pharmacology, biomarker, and data platforms. A conference call will follow on the same day at 8:30 a.m. EDT to discuss the financial results. Stakeholders can join by calling 877-407-8035. A recording of the call will be available post-event.
Champions Oncology (NASDAQ:CSBR) has announced a strategic partnership with BGI Americas, enhancing their Lumin Bioinformatics platform. This collaboration grants BGI access to Champions' extensive cancer datasets, facilitating advanced analysis of proteomics data for their clients. BGI will utilize its Mass Spectrometry Center to assist in biomarker discovery and validation solutions, allowing both companies to offer a streamlined workflow from data generation to interpretation. This partnership positions Champions as a leader in data-driven oncology solutions.
Champions Oncology (NASDAQ:CSBR) reported impressive third-quarter financial results for fiscal 2021, achieving a record revenue of $10.8 million, a 20% year-over-year increase. The company reported a non-GAAP income from operations of $1.3 million, up from $881,000 in the same quarter last year. Despite a rise in total operating expenses by 17.1% to $10 million, Champions continues to invest in product development and expansion. Their cash balance improved significantly to $7.4 million compared to $3.3 million a year ago, with no debt reported.
Champions Oncology, Inc. (NASDAQ:CSBR) will announce its third-quarter financial results for the period ending January 31, 2021, on March 11, 2021, after the market closes. A conference call to discuss the results will take place at 4:30 p.m. EST on the same day. Interested parties can join by calling 877-407-8035 (Domestic) or 201-689-8035 (International). A replay will be available shortly after the call. Champions Oncology focuses on transforming drug discovery through innovative pharmacology and data platforms.
Champions Oncology (NASDAQ:CSBR) announced the appointment of Rob Brainin to its Board of Directors, enhancing its expertise in drug discovery through innovative data platforms. With over 15 years in life sciences, Brainin is expected to accelerate the company's data platform development. His previous leadership roles include CEO of Genuity Science and VP at Illumina. The company also noted the resignation of board member Abba Poliakoff, thanking him for his contributions.
Champions Oncology, Inc. (NASDAQ:CSBR) announced a partnership with Code Ocean on January 19, 2021, aimed at enhancing its Lumin Bioinformatics SaaS program. The collaboration focuses on improving data integration and sharing workflows, allowing users to centralize their code and data securely. This enhancement positions Lumin as an enterprise-level solution, broadening its market potential. The partnership addresses unstructured data within research centers, aiming to turn Lumin into a foundational tool for oncology research.
Champions Oncology (NASDAQ:CSBR) announced the expansion of its Lumin Bioinformatics program, which now includes over 20,000 datasets, enhancing its proteomic data capabilities. This initiative aims to provide researchers with advanced analysis tools to better understand tumor biology and therapeutic resistance. The integration of proteomics into Lumin allows for direct insights into protein expression, moving beyond traditional RNA and DNA sequencing methods. Key executives highlighted the potential of this expanded dataset to transform cancer research and improve data accessibility for scientists.
Champions Oncology (NASDAQ:CSBR) announced record quarterly revenue of $10.1 million for Q2 fiscal 2021, a 33% increase year-over-year. The company launched its proprietary Lumin Bioinformatics SaaS platform, enhancing drug discovery capabilities. Income from operations, excluding stock-based compensation, was $400,000, although total operating expenses rose 37.9% to $10.1 million. The gross margin declined to 44.2% due to increased costs. The company raised its full-year revenue guidance to 20%-25%.
Champions Oncology, Inc. (CSBR) will report its financial and operational results for the second quarter on December 14, 2020, after market close. A conference call will be held at 4:30 p.m. EST to discuss the results. The company specializes in oncology technology solutions aimed at transforming drug discovery through advanced pharmacology and biomarker data platforms. Champions is noted for its innovative approach to personalizing cancer care with its Champions TumorGrafts technology.
FAQ
What is the current stock price of Champions Oncolo (CSBR)?
What is the market cap of Champions Oncolo (CSBR)?
